I went out on a limb last week, and now it's time to see how that decision played out.

I predicted that IMAX NYSE:IMAX)

I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average . DJINDICES:^DJI)

would outperform the . My final call was for Constellation Brands NYSE:STZ)

Two out of three? I can do better than that.

Let me once again whip out my trusty, dusty, and occasionally accurate crystal ball to make three calls that may play out over the next few trading days.

1. Noodles & Co. will close lower on the week

It's clear that the market is hungry for Noodles & Co. (NASDAQ:NDLS), the fast-casual dining chain that has seen its shares soar 161% in its first five trading days as a public company.

Is this really a $1.3 billion company, though? Revenue growth in the teens and positive comps in 28 of the past 29 quarters is impressive, but not for a company that rang up just $300 million in sales last year. This should be a solid investment once it settles in at a much more reasonable valuation, but for now it's just not worth the hype.

My first call is for Noodles & Co. to close lower on the week.

2.The Nasdaq Composite will beat the Dow this week

Tech has been a big winner in recent years, so betting on tech over stodgy blue chips has been a good bet for me more often than not.

I'm going to stick with this pick. Most of the names in the composite are just too cheap at this point, and tech should be what carries us through the economic recovery. The market is ripe for the tech-stacked secondary stocks to continue to outpace the 30 megacaps that make up the Dow Jones Industrial Average.

3.Peregrine Pharmaceuticals will beat Wall Street's earnings estimates

Some stocks are just flat-out better than others.

Peregrine Pharmaceuticals (NASDAQ: PPHM) is an upstart biotech targeting the treatment and diagnosis of cancer through monoclonal antibodies. It has a potential winner in its lead candidate that will begin its telltale phase 3 clinical trial later this year.

Another thing it does is make analysts look like perpetual underachievers. If analysts say the company posted a loss of $0.06 a share in its latest quarter, I'll argue that it held up better than that. History's on my side!

One of my best tricks to beating the market is finding stocks that perpetually land ahead of the prognosticators. Let's go over the past year of earnings reports.

Quarter EPS Estimate EPS Surprise Q4 2012 ($0.13) ($0.10) 23% Q1 2013 ($0.11) ($0.07) 36% Q2 2013 ($0.09) ($0.08) 11% Q3 2013 ($0.07) ($0.04) 43%

Things can change, of course. Despite posting lower deficits with every passing a quarter -- a welcome trend in and of itself in eyeing the loss that analysts are forecasting -- it's certainly not cheap to ramp up pivotal late-stage clinical trials.

However, it's hard to argue against the trend. Everything seems to be falling into place for another market-thumping quarter on the bottom line.

Three for the road

Well, there are three predictions right there. Let's see how I fare this week.